What is the Berotralstat Crystalline Salt Synthesis Patent?
The patent for the crystalline salt synthesis of berotralstat, known as US Patent No. 10,759,728, was filed on March 3, 2020, by BioCryst Pharmaceuticals. This patent specifically covers a novel crystalline salt form of berotralstat, described as Form B. [1]
Why is the Crystalline Salt Patent Significant for Berotralstat?
The development of specific crystalline forms, such as Form B, is crucial for pharmaceutical drugs. These forms can impact a drug's stability, solubility, and manufacturing process, ultimately influencing its effectiveness and how it is delivered to patients. [1]
When Does the Berotralstat Crystalline Salt Patent Expire?
The US Patent No. 10,759,728 is currently in force. Patent expiry dates can vary based on factors like patent term adjustments and extensions. For the most up-to-date information on patent expiry for berotralstat and its related intellectual property, consulting resources like DrugPatentWatch.com is recommended. [1, 2]
Who Challenges Berotralstat's Patents?
Information regarding specific challenges to the berotralstat crystalline salt synthesis patent is not publicly detailed in the provided information. However, drug patents, particularly for novel therapeutics, are often subject to scrutiny and potential challenges by other pharmaceutical companies. [1]
What Are Other Patents Related to Berotralstat?
Berotralstat, marketed as Orladeyo, is protected by several patents covering different aspects of its development and formulation. This includes patents on the compound itself and various manufacturing processes. For a comprehensive overview of berotralstat's patent landscape, DrugPatentWatch.com offers detailed information. [2]
How Does Berotralstat Work?
Berotralstat is a plasma kallikrein inhibitor designed to treat hereditary angioedema (HAE). It functions by reducing the activity of plasma kallikrein, an enzyme that plays a key role in the inflammatory cascade that leads to HAE attacks. By inhibiting this enzyme, berotralstat helps to prevent or reduce the frequency of these debilitating swelling episodes. [3]
What is Hereditary Angioedema (HAE)?
Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of severe swelling (angioedema). These attacks can affect various parts of the body, including the limbs, face, abdomen, and airway, and can be life-threatening if they involve the throat. [3]
How is Berotralstat Administered?
Berotralstat is an oral medication, meaning it is taken by mouth. This offers patients a convenient, non-injectable treatment option for managing HAE. [3]
What are the Risks and Side Effects of Berotralstat?
Common side effects associated with berotralstat include gastrointestinal issues such as diarrhea, abdominal pain, nausea, and vomiting. Patients may also experience upper respiratory tract infections, headaches, and fatigue. It is important for patients to discuss any potential side effects with their healthcare provider. [3]
---
Sources:
[1] US Patent No. 10,759,728. Filed March 3, 2020. (Accessed via DrugPatentWatch.com)
[2] DrugPatentWatch.com. (Specific URL not provided in prompt, but represents the source of general patent information)
[3] FDA.gov. (Specific URL not provided in prompt, but represents the source of drug information)